The FDA has approved four autologous CD19 targeted CAR-T cell therapy products, Tisagenlecleucel (Kymriah), Axicabtagene ciloleucel (Yescarta), Brexucabtagene autoleucel (Tecartus), Lisocabtagene maraleucel (Breyanzi) for relapsed/refractory B-cell lymphoma or acute lymphocytic leukemia, and one autologous BCMA targeted CAR-T cell therapy product, Idecabtagene vicleucel (Abecma) for multiple myeloma (7–11). Here, CD19 is linked to B-cell non-Hodgkin lymphoma.